Patents Assigned to BroadenBio Co., Ltd.
  • Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
    Patent number: 12715873
    Abstract: Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: August 25, 2026
    Assignee: BroadenBio Co., Ltd.
    Inventors: Gongping Duan, Xingmin Zhang, Zhihua Wang, Xianglong Wei, Min Li
  • Bridged cycloformylpyridine derivatives and uses thereof
    Patent number: 12344611
    Abstract: Provided are a compound of formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and a use thereof. The above-mentioned compound has a very strong inhibitory effect on the FGFR4 kinase activity and the proliferative activity of Hep 3B cells with high FGFR4 expression.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: July 1, 2025
    Assignee: BroadenBio Co., Ltd.
    Inventors: Qi Wang, Gongping Duan, Wei Hua, Xingmin Zhang
  • PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20230322789
    Abstract: Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 12, 2023
    Applicant: BroadenBio Co., Ltd.
    Inventors: Gongping Duan, Xingmin Zhang, Zhihua Wang, Xianglong Wei, Min Li
  • BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF
    Publication number: 20230012600
    Abstract: Provided are a compound of formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and a use thereof. The above-mentioned compound has a very strong inhibitory effect on the FGFR4 kinase activity and the proliferative activity of Hep 3B cells with high FGFR4 expression.
    Type: Application
    Filed: October 21, 2020
    Publication date: January 19, 2023
    Applicant: BroadenBio Co., Ltd.
    Inventors: Qi Wang, Gongping Duan, Wei Hua, Xingmin Zhang